



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

April 8, 2013

Via E-Mail

Jeffrey Bacha
Chief Executive Officer and President
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, BC
Canada V5Z 1K5

**Re: DelMar Pharmaceuticals, Inc.
Current Report on Form 8-K
Filed January 31, 2013, as amended
File No. 000-54801**

Dear Mr. Bacha:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Jennifer Riegel for

Jeffrey P. Riedler
Assistant Director

cc: Via E-Mail
Jeff Cahlon
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, NY 10006